Major changes at women’s health company

  • Dare Bioscience is losing its CFO, chief commercial officer, and two directors
  • Lisa Walters-Hoffert has retired as CFO
  • John Fair will resign as chief commercial officer
  • No successor planned for Walters-Hoffert
  • CEO Sabrina Martucci Johnson will take over as principal financial officer
  • MarDee Haring-Layton promoted to chief accounting officer
  • Fair’s resignation tied to the full-scale commercial launch of Dare’s vaginal gel Xaciato
  • Cheryl Blanchard and Sophia Ononye-Onyia voluntarily leaving the board
  • Board size to be reduced from eight members to six

Dare Bioscience, a San Diego-based women’s health company, is experiencing significant changes in its leadership. Lisa Walters-Hoffert, the chief financial officer, has retired, while John Fair, the chief commercial officer, will resign this summer. The company does not plan to appoint a successor for Walters-Hoffert, and instead, CEO Sabrina Martucci Johnson will take over as the principal financial officer. Additionally, MarDee Haring-Layton, the current vice president of accounting and financing, will be promoted to chief accounting officer. Fair’s decision to step down is tied to the full-scale commercial launch of Dare’s vaginal gel Xaciato, which was one of his primary responsibilities. In addition to the executive changes, Dare Bioscience is also reducing the size of its board with the voluntary departures of Cheryl Blanchard and Sophia Ononye-Onyia. The board will be reduced from eight members to six.

Public Companies: Dare Bioscience (N/A)
Private Companies:
Key People: Lisa Walters-Hoffert (Chief Financial Officer), John Fair (Chief Commercial Officer), Sabrina Martucci Johnson (Chief Executive), MarDee Haring-Layton (Vice President of Accounting and Financing), Cheryl Blanchard (Director), Sophia Ononye-Onyia (Director)

Factuality Level: 8
Justification: The article provides factual information about the departure of the chief financial officer, chief commercial officer, and two directors of Dare Bioscience. It also mentions the company’s plans for succession and board reduction. The information is straightforward and does not contain any obvious bias or opinion.

Noise Level: 3
Justification: The article provides clear and concise information about the departure of the CFO, CCO, and two directors of Dare Bioscience. It includes details about their replacements and the reasons for their departures. However, it lacks in-depth analysis, evidence, or insights into the long-term implications or consequences of these changes.

Financial Relevance: Yes
Financial Markets Impacted: No

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: This news article pertains to financial topics as it discusses the departure of the chief financial officer and chief commercial officer of Dare Bioscience, a women’s health company. However, there is no mention of any extreme event or its impact.

Reported publicly: www.marketwatch.com